Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: The Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial

Background Iso-osmolar contrast medium iodixanol has been reported to be less nephrotoxic than selected low-osmolar contrast media (LOCM) in chronic kidney disease (CKD) patients with diabetes mellitus. This study compared the nephrotoxicity of iodixanol and the LOCM ioversol in CKD patients undergo...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2008-10, Vol.156 (4), p.776-782
Main Authors: Rudnick, Michael R., MD, FACP, FASN, Davidson, Charles, MD, FACC, Laskey, Warren, MD, FACC, Stafford, J. Lawrence, MD, FACC, Sherwin, Paul F., MD, PhD
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Blood diseases
Blood pressure
Cardiovascular
Contrast agents
Contrast Media - adverse effects
Coronary Angiography
Coronary Disease - diagnostic imaging
Coronary Disease - epidemiology
Creatinine - blood
Diabetes
Diabetic Angiopathies - diagnostic imaging
Diabetic Angiopathies - epidemiology
Diabetic Nephropathies - physiopathology
Diuretics
Double-Blind Method
Drug therapy
Enzymes
Female
Heart attacks
Humans
Kidney - drug effects
Kidney diseases
Laboratories
Male
Medical imaging
Middle Aged
Prospective Studies
Renal Insufficiency, Chronic - epidemiology
Renal Insufficiency, Chronic - physiopathology
Review boards
Studies
Triiodobenzoic Acids - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Iso-osmolar contrast medium iodixanol has been reported to be less nephrotoxic than selected low-osmolar contrast media (LOCM) in chronic kidney disease (CKD) patients with diabetes mellitus. This study compared the nephrotoxicity of iodixanol and the LOCM ioversol in CKD patients undergoing coronary angiography. Methods This is a prospective double-blind trial in 337 patients with stable CKD who were randomly assigned to receive the iso-osmolar contrast medium iodixanol or the LOCM ioversol. The co-primary end points were the mean peak percentage change (MPPC) in baseline serum creatinine and the incidence of contrast-induced nephropathy (rise of >0.5 mg/dL in baseline serum creatinine within 72 hours postcontrast) for the 2 contrast media in the 72-hour period after contrast administration. Prespecified analyses included stratification on diabetic state and the use of N -acetylcysteine. Results In the 299 patients with complete post–contrast media creatinine data, the incidence of contrast-induced nephropathy was 21.8% in the iodixanol subjects and 23.8% in the ioversol subjects ( P = .78). For all patients, the MPPC was 14.7% with iodixanol and 20.0% with ioversol ( P = .06), whereas in the subset of diabetic patients, this value was significantly lower in the iodixanol (12.9%) compared with the ioversol subjects (22.4%, P = .01). Conclusions Overall, the nephrotoxicity associated with iodixanol was not significantly different from that observed with ioversol in CKD patients undergoing coronary angiography, although in diabetic patients, MPPC was significantly lower in the iodixanol group.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2008.05.023